Q-omics provides the consensus-scored RDM1P2 profile across patient tissues and cancer cell-line models. RDM1P2 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RDM1P2 is differentially expressed in 1, with the highest sampling consensus in KICH. Additionally, RDM1P2 RNA expression shows 3,960 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight UVM, KICH, and KIRC as cancer lineages where RDM1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RDM1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RDM1P2 survival associations across molecular data types. RDM1P2 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RDM1P2 RNA expression–survival associations across cancer types. High RDM1P2 expression shows unfavorable associations in UVM, STAD, BRCA, LUAD and PAAD, but favorable associations in SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RDM1P2 RNA expression.
This table summarizes RDM1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for RDM1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RDM1P2 shows lower tumor expression in KICH. The KICH box plot shows higher RDM1P2 RNA expression in normal versus tumor tissue (log2 FC = −0.065, t-test p = .031).
This table shows molecular features associated with RDM1P2 in patient tissues and cancer cell lines. In patient samples, RDM1P2 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
